



RECEIVED

JUN 01 2001

TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents

Washington, D.C. 20231 on May 24, 2001

AMENDMENT UNDER
37 CFR §1.825(a) THROUGH (c)
Examining Group 1632
Patent Application
Docket No. GJE-30
Serial No. 09/297,486

Doran R. Pace
Doran R. Pace, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Richard Schnizer
Art Unit : 1632
Applicants : John Francis Martin, Seppo Yla-Herttuala, Stephen George Edward Barker
Serial No. : 09/297,486
Filed : April 30, 1999
For : Therapeutic Use of an Agent That Stimulates NO or Prostacyclin Production and Delivery Device

Box SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT UNDER 37 CFR §1.825(a) THROUGH (c)

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures received in the above-identified patent application, please amend the subject application as follows, in order to comply with the requirements of 37 CFR §§1.821-1.825:

In the Specification

Please replace original pages 52-64 (Sequence Listing) with new pages 52-60 attached hereto.

In the Claims

Please renumber original pages 65-67 (Claims) as pages 61-63.